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Abstract 8 
Purpose: We investigated associations between athletes’ use of sport supplements and their 9 
responsiveness to placebo and nocebo interventions. Methods: Participants (n=627) reported 10 
their intention to use, and actual use of, sport supplements. They then completed a 5x20m 11 
repeat sprint protocol in the baseline condition, prior to being randomized to one of three 12 
treatments. Participants in the positive-belief treatment were administered an inert capsule 13 
described as a potent supplement which would improve sprint performance. Participants in the 14 
negative-belief treatment were administered an inert capsule described as a potent supplement 15 
which would negatively affect sprint performance. Participants in the control treatment 16 
received neither instruction nor capsule. 20 minutes following baseline trials, all participants 17 
completed the same repeat sprint protocol in the experimental condition. Results: Compared 18 
to controls, no mean differences in performance were observed between baseline and 19 
experimental conditions for the positive-belief treatment (-0.07 ± 0.27%, d=0.02), but mean 20 
differences were observed for the negative-belief treatment (-0.92 ± 0.31%, d=0.32), 21 
suggesting a moderate nocebo effect. In the positive-belief treatment however, a relationship 22 
between intention to use supplements and performance was observed. Performance worsened 23 
by -1.10% ± 0.30% compared to baseline for participants not intending to use supplements, 24 
worsened by -0.64 ± 0.43% among those undecided about supplement use, but improved by 25 
0.19 ± 0.24% among those participants intending to use supplements. Conclusion: Information 26 
about a harmful supplement worsened repeat sprint performance (a mean nocebo effect), 27 
whereas information about a beneficial supplement did not improve performance (no mean 28 
placebo effect was observed). However, participants’ intention to use sport supplements 29 
influenced the direction and magnitude of subsequent placebo responses, with participants 30 
intending to use supplements more likely to respond to the positive intervention.  31 
Key words: Nocebo, responders, beliefs, ergogenic aids   32 
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Introduction 33 
A placebo effect is a positive psychobiological response to a purported beneficial treatment 34 
(11). Placebo effects have been extensively studied in sport (3, 4, 7, 8, 12, 15, 21, 31, 32, 34, 35 
35, 39), with a systematic review (6) reporting that placebo treatments can exert a significant 36 
effect on sport performance. For example, Ross et al. (34) reported a 1.2% improvement in 3-37 
km running time-trial performance when participants self-administered saline injections 38 
believing it to be a performance enhancing substance. Likewise, Saunders et al. (35) reported 39 
that mean power output improved by 3.7% among cyclists deceptively administered a placebo 40 
when they believed they had ingested caffeine.  41 
While there is empirical support for the potential role of the placebo effect in sports 42 
performance, there is less evidence for the nocebo effect; that is, a negative psychobiological 43 
response to a purported harmful treatment. Arguably the first study of the nocebo effect in sport 44 
was conducted by Beedie et al. in 2007 (5). These authors reported that n=21 participants who 45 
believed they had ingested a placebo, that is a capsule described as a beneficial sport 46 
supplement, ran progressively faster compared to baseline. Likewise, n=21 participants who 47 
believed they had ingested a nocebo, that is a capsule described as a supplement likely to be 48 
detrimental to performance, ran progressively slower compared to baseline. Findings 49 
highlighted the potentially significant impact of positive and negative expectations on sports 50 
performance.  51 
However, the study in question (5) lacked a no-treatment control. It is therefore problematic to 52 
estimate the true relative magnitude of the placebo and nocebo effects reported; changes in 53 
performance could be attributed to statistical or methodological artefacts such as regression to 54 
the mean or spontaneous improvements/decrements in performance (25). Further, it is 55 
problematic from this uncontrolled study to discern whether actual effects were all positive, all 56 
negative, or whether both placebo and nocebo effects occurred. As a result, the reported 57 
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magnitude of either the nocebo or placebo effect might have been overestimated. Further, while 58 
the n=42 reported was relatively large for an intervention study in sport, it was however too 59 
small to facilitate the reliable identification of any psychosocial variables that might have been 60 
associated with the placebo and nocebo responses observed.  61 
In most studies of the placebo/nocebo effect in sport, the standard deviation of the dependent 62 
measure is greater in experimental conditions than at baseline (6). This suggests that, even if a 63 
mean placebo effect is observed, there is considerable inter-individual variability in response 64 
to the treatment. Few studies have attempted to identify the variables related to placebo 65 
responses, and those that have are perhaps methodologically unsatisfactory. For example, 66 
Beedie et al. (7) identified a possible link between placebo responding and personality factors, 67 
but the sample size was too small for their findings to be considered reliable. In fact, the small 68 
sample sizes of nearly all studies of the placebo effect in sport has precluded the reliable 69 
investigation of any factor that might be associated with placebo responding. If our knowledge 70 
and understanding of the placebo and nocebo effects is to progress beyond simple description, 71 
we need to better understand the relevant antecedents and mechanisms.  72 
We aimed to extend Beedie et al.’s study (5) via two specific criteria, each allowing us to test 73 
two novel hypotheses. First, by using a no-treatment control we were able to estimate the 74 
relative magnitude of placebo and nocebo effects in response to treatments. In this context we 75 
hypothesised that compared to controls, positive effects on performance would be associated 76 
with a positive belief (placebo) treatment, while negative effects on performance would be 77 
associated with a negative belief (nocebo) treatment. Second, by using a sufficiently large 78 
sample, we were able to reliably identify factors that might be associated with observed placebo 79 
and/or nocebo responses. Given the range of such factors is potentially large, we were 80 
presented with a number of possible hypotheses. Recent data from both medicine and 81 
psychology suggest that prior use of a treatment can influence the response of a patient to a 82 
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subsequent placebo treatment (10). We hypothesised that athletes with prior experience of sport 83 
supplements would be more likely to respond to a placebo sport supplement than those who do 84 
not use sport supplements. Furthermore, prior use of a supplement is suggested to be influenced 85 
via a person’s intention to use that substance (33). We therefore further hypothesised that those 86 
intending to use supplements would also be more likely to respond to a placebo intervention.  87 
The idea that greater understanding of the placebo effect among athletes and coaches might 88 
reduce doping has been proposed (6, 26, 31, 32). Given the gateway hypothesis (26), which 89 
posits that supplement use can lead to doping, it is reasonable to suggest that, over and above 90 
enhancing our understanding of placebo and nocebo effects in sport, this study could also 91 
enhance our understanding of factors that underpin doping.  92 
Methods 93 
Design 94 
The placebo and nocebo interventions used in this study required the deceptive administration 95 
of an inert capsule delivered to members of teams in their usual team environment. We 96 
therefore used a cluster randomized controlled trial design to minimize cross-contamination 97 
between experimental and control treatments. Participants completed a pre-experimental 98 
questionnaire relating to sport supplementation, before performing 5 × 20-m repeat sprint with 99 
30s recovery at baseline. Following Beedie et al.’s original design (5), participants in the 100 
positive-belief treatment (n = 288) were deceptively administered an inert capsule described as 101 
a potent supplement which would improve sprint performance. Also following the original 102 
design, participants in the negative-belief treatment (n = 232) were deceptively administered 103 
an inert capsule described as a potent supplement which would negatively affect sprint 104 
performance. However, extending the original study, no-treatment control participants (n = 105 
192) received neither instruction nor placebo. Twenty minutes following the administration of 106 
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the capsules, participants completed the experimental condition, which was a repeat of the 5 × 107 
20-m sprints.  108 
Participants 109 
We used convenience sampling, and invited athletes from a range of sports to participate in the 110 
study. Seven hundred and twelve competitive athletes from 43 different teams (number of 111 
athletes in each team: median = 14; range = 8 to 40) were initially recruited to the study. 112 
Participant demographics are presented in Table 1. All participants were aware that their 113 
involvement in the study was voluntary and that all data collected would be treated as 114 
confidential. Ethical approval was granted by the Institutional Research Ethics Committee. 115 
Participants gave written informed consent once they had read the participant information 116 
sheet. 117 
Measures 118 
Pre-experimental questionnaire 119 
All participants were asked to complete a pre-experimental questionnaire detailing sex, age, 120 
sport played and competitive level (club, county, regional or national). They were asked to 121 
indicate whether they used sports supplements (yes or no), the total number of supplements 122 
used, and the frequency of use (daily, weekly, monthly or never). They were also asked to 123 
indicate their agreement with a statement of their intention to use sport supplements in the next 124 
three months on a 6 point Likert-type scale anchored at strongly disagree (1), through to 125 
strongly agree (6). Those scoring 1 and 2 were grouped as ‘not intending’, 3 and 4 as 126 
‘undecided’, 5 and 6 as ‘intending’. 127 
Repeat sprint performance 128 
Whereas Beedie et al. (5) used a 3 × 30-m repeat sprint protocol, Schimpchen, Skorski, Nopp 129 
and Meyer (36) reported that four or more sprints should be used to decrease the typical error 130 
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and improve the precision of estimating true changes in performance. Furthermore, the 131 
majority of sprinting in team sports events occurs over relatively short distances (i.e. <30-m; 132 
(14)) and short durations (i.e. <4 seconds; (37)). For these reasons, participants were asked to 133 
complete five 20-m maximal intensity repeat sprints with 30 seconds of recovery between each 134 
sprint. Sprint time was measured using an automated, single-beam photocell, light gate system 135 
(Smartspeed ProTM, Fusion Sport Inc., Australia). Single-beam light gate systems are the most 136 
common method for measuring sprint performance and have been shown to have good 137 
reliability (20).  138 
Belief Manipulation 139 
During the 20-minute recovery period between baseline and experimental conditions, 140 
participants in the positive- and negative-belief treatments were given a capsule described as a 141 
potent sport supplement, ‘inorganic nitrate.’ Similar to Beedie et al. (5), the positive-belief 142 
treatment participants were given two red and white, size 1 (20-mm), gelatine capsules 143 
containing 200-mg of cornflour (Sainsbury’s, London UK) and informed that inorganic nitrate 144 
would improve both endurance and repeat sprint performance. Negative-belief treatment 145 
participants were given two red and black, size 1 (20-mm), gelatine capsules containing 200-146 
mg of cornflour and informed that inorganic nitrate would improve endurance but have a 147 
negative effect on sprint speed. The effectiveness of the belief manipulation was assessed 148 
during a debrief immediately following the experimental trials, at which point the true nature 149 
of the study was revealed. Participants were asked to respond on a 10 point Likert-type scale, 150 
how much they believed the treatment influenced their performance (1 = no influence to 10 = 151 
high influence).  152 
Procedure 153 
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Testing was performed at the 43 different training facilities habitually used by the teams 154 
recruited to the study. All data per each participant were collected on one day to minimize 155 
meteorological and biological variation. Teams were randomised to the three treatments (i.e. 156 
positive, negative and control) using a computer generated cluster programme (allocation ratio 157 
1:1:1), which was performed by the lead author who was also involved in delivering the 158 
intervention. To reduce potential confounding, only one team per club were permitted to take 159 
part in the study. All treatments were conducted on separate days and at separate sites to 160 
maintain the experimental blind.  161 
Participants completed the sprints in footwear and clothing suitable for high intensity exercise, 162 
and were encouraged to perform their standard warm-up. They began each sprint in a stationary 163 
position, ~50-cm behind the first light gate. They were instructed not to rock back and forth 164 
prior to the sprint, but were permitted to start the sprint in any position (e.g. split-stance or 165 
crouch start), which was replicated for each sprint. Each sprint was started by a green LED, 166 
which would flash up on the photocell. Participants were encouraged to sprint as fast as 167 
possible for the full 20-m, with times recorded to the nearest 1/100th of a second. Participants 168 
were given thirty seconds to jog back to the start position and begin the next sprint. This process 169 
was continued until each participant had completed five sprints.  170 
After the baseline condition, participants in the positive- and negative-belief treatments 171 
received the capsules and the belief manipulation. All participants then completed a 20-minute 172 
recovery consisting of light exercise to minimize the search for physiological symptoms 173 
associated with the intervention (16), before commencing the experimental condition in the 174 
same manner as the first. The total duration of the repeat sprint protocol, including recovery, 175 
was less than 30-minutes per participant. On completion, participants were debriefed about the 176 
true nature of the study in line with American Psychological Association guidelines for 177 
deceptive research (1). 178 
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Statistical analysis 179 
Data were inputted into SPSS version 23.0 (IBM, Armonk, NY, USA) and tested for 180 
homogeneity of variance, normal distribution and anomalies. Inspection of the data indicated 181 
that 55 participants (8%) did not complete the experimental condition (positive-belief treatment 182 
n = 20; negative-belief treatment n = 16; control n = 19). In addition, data values that exceeded 183 
2.5 times the standard deviation were identified as extreme outliers (30).  Thirty participants 184 
(4%) were identified as extreme outliers (positive-belief treatment n = 7; negative-belief 185 
treatment n = 7; control n = 16) and were subsequently removed from further analysis (27). 186 
Data for the remaining sample of 627 participants (positive-belief treatment n = 261; negative-187 
belief treatment n = 209; control n = 157) were entered into subsequent statistical analyses.  188 
One-way Analysis of Variance (ANOVA) and chi-square (χ2) tests were used to compare 189 
continuous (years training, hours per week training and number of supplement used) and 190 
categorical (sex, age, sport, ability, supplement use, frequency of supplement use and intention 191 
to use supplements) variables between treatments, respectively.  192 
Sprint times for each condition (i.e. baseline and experimental) and treatment (i.e. positive, 193 
negative and control) were inputted into Hopkins’ (22) reliability spreadsheet. Data were log 194 
transformed to reduce non-uniform errors and the intra-class correlation (ICC) provided 195 
estimates of reliability. The precision of ICC was interpreted as extremely high = 0.99; very 196 
high = 0.90; high = 0.75; moderate = 0.50; low = 0.20 (22).  197 
Hopkins, Hawley and Burke (24) suggest that research investigating athletic performance 198 
should report outcome as a percentage change from baseline. Sprint times were therefore 199 
converted to the proportion of the first sprint speed, expressed as a percentage. Differences 200 
between participant’s average performance for each condition (i.e. performance average for 201 
baseline [sprints 1 to 5] and experimental conditions [sprints 6 to 10]), and the difference in 202 
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the fastest sprint trial in each condition (i.e. fastest individual sprint at baseline minus fastest 203 
individual sprint at experimental) were calculated. 204 
Repeated measures ANOVA identified differences in sprint performance between each 205 
condition, with treatment included as a between-subject factor. Greenhouse-Geisser epsilon 206 
was reported where sphericity was violated, and post-hoc LSD tests were conducted where a 207 
significant interaction was observed. Point-Biserial correlations (rpb) were used to assess the 208 
relationship between performance and categorical variables (i.e. sex, age, ability, sport 209 
supplement use, frequency of sport supplement use, intention to use sport supplements, belief 210 
manipulation scores). Data of the variables that correlated significantly with performances 211 
were further analysed using repeated measures ANOVA and Multivariate ANOVA 212 
(MANOVA). Given the possibility that differences between treatments may reflect the large 213 
sample size and sampling variability (38), Cohen’s d (d) effect sizes were calculated. 214 
Differences between 0.2 and <0.5 were interpreted as a small effect, between 0.5 and <0.8 as 215 
moderate, and ≥0.8 as large (13). Data are presented as mean ± standard error of the mean 216 
(SEM), with statistical significance accepted at P ≤0.05. 217 
Results 218 
Participant demographics 219 
No significant differences were observed between treatments for number of years training 220 
(F (2,573) = 2.072, P = 0.127), hours per week training (F (2,580) = 0.403 P = 0.669), sex (χ2 = 5.28, 221 
P = 0.071), supplement use (χ2 = 2.32, P = 0.312), frequency of supplement use (χ2 = 6.50, P = 222 
0.370) and intention to use supplements (χ2 = 4.65, P  = 0.098). Differences between treatments 223 
were observed for age (χ2 = 21.99, P = 0.001), ability (χ2 = 21.69, P = 0.001) and sport played 224 
(χ2 = 225.76, P  < 0.001). Covariate analysis, adjusting for the differences in categorical 225 
11 
 
variables, revealed no effect on the outcome of the performance sprint data (P >0.05). The 226 
results of the subsequent analyses are therefore reported with unadjusted covariate data. 227 
Reliability of sprint trials 228 
Baseline sprints (i.e. trials 1 – 5) were associated with very high reliability in the positive-belief 229 
treatment (ICC = 0.94), negative-belief treatment (ICC = 0.96) and control treatment (ICC = 230 
0.90). Similar reliability coefficients were also observed for experimental sprints (i.e. trials 6 – 231 
10) in the positive-belief treatment (ICC = 0.94), negative-belief treatment (TE = 0.94) and 232 
control treatment (ICC = 0.94).  233 
We also investigated the possibility that greater reliability was associated with fewer than 5 234 
sprint trials. If for example, reliability between sprint trials 1 – 4 or 1 – 3 are more reliable than 235 
1 – 5, this could reduce the error and improve the chances of finding a true effect of the 236 
intervention on sprint performance. ICC’s were however, similar for trials 1 – 4 (ICC range = 237 
0.92 to 0.96) and 1 – 3 (ICC range = 0.93 to 0.96). Therefore, sprint trials 1 – 5 are reported in 238 
the subsequent analysis.   239 
Differences in baseline and experimental performance between treatments 240 
No between-treatment differences were observed at baseline (F (2,624) = 0.149, P = 0.861). 241 
However, between-treatment differences were observed in experimental trials (F (2,624) = 5.879, 242 
P = 0.001). In the negative-belief treatment, performance was worse than at baseline (-1.42 ± 243 
0.15%, P <0.001, d = 0.56), and also worse than performance in the positive-belief treatment 244 
(-1.04 ± 0.28%, P <0.001, d = 0.34) and in the control treatment (-0.92 ± 0.31%, P <0.001, d 245 
= 0.32). No differences were observed between the positive-belief and control treatments (-246 
0.07 ± 0.27%, P = 0.696, d = 0.02). Figure 1 illustrates the differences in performance for each 247 
condition between treatments.  248 
Correlations between performance and categorical variables 249 
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Point-Biseral correlations revealed a significant relationship between participant’s intention to 250 
use supplements and performance (average performance in each condition: rpb = 0.106, P = 251 
0.012; fastest performance difference between conditions: rpb = 0.101, P = 0.016). No other 252 
significant relationships were observed between other categorical variables for average 253 
performance in each condition  (sex rpb = -0.009, P = 0.819; age rpb = 0.006, P  = 0.891; ability 254 
rpb = -0.039, P = 0.353; use of supplements rpb = 0.071, P = 0.078; frequency of supplements 255 
rpb = 0.075, P = 0.074; belief manipulation scores rpb = -0.035, P = 0.563) or fastest 256 
performance between conditions (sex rpb = -0.014, P  = 0.723; age rpb = 0.005, P  = 0.906; ability 257 
rpb = -0.042, P = 0.318; use of supplements rpb = 0.075, P = 0.071; frequency of supplements 258 
rpb = -0.062, P = 0.135; belief manipulation scores: rpb = 0.025, P = 0.677; fastest performance: 259 
rpb = 0.025, P = 0.677).  260 
Differences in baseline and experimental performance between supplement intention  261 
Further analysis using repeated measures ANOVA identified differences in participant’s repeat 262 
sprint performance in each treatment by intention to use sport supplements (i.e. not intending; 263 
n = 174; undecided; n = 112; and intending; n = 284). No differences between baseline and 264 
experimental conditions were observed for participants in the positive-belief treatment 265 
intending to use supplements (0.28 ± 0.14%, P = 0.886, d = 0.01). However, sprint performance 266 
worsened for participants in the positive-belief treatment who were undecided about 267 
supplement use (-0.67 ± 0.36%, P = 0.039; d = 0.22), and not intending to use sport 268 
supplements (-0.64% ± 0.25, P = 0.036; d = 0.23; figure 2A). No differences in sprint 269 
performance by intention to use supplements were observed in the negative-belief (figure 2B) 270 
and control (figure 2C) treatments (P >0.05). 271 
Between-treatment differences in fastest performance by intention 272 
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Differences in fastest sprint performance and intention to use supplements were analysed using 273 
MANOVA. The performance of participants intending to use supplements in the positive-belief 274 
treatment was more positive compared to that of participants in the negative-belief treatment 275 
(1.29 ± 0.37%, P = 0.001, d = 0.51) and control treatment (0.90 ± 0.41%, P = 0.029, d = 0.33). 276 
Performance for participants not intending to use supplements in the negative-belief treatment 277 
was worse compared than controls (negative-belief vs. controls = -1.34 ± 0.48%, P = 0.005, d 278 
= 0.52). This trend was similar between the positive-belief and control treatment (-0.91 ± 279 
0.45%, P = 0.060; d = 0.38). No differences were observed for participant’s undecided about 280 
supplement use between all three treatments (P > 0.05; figure 3). 281 
Within-treatment differences in fastest performance by intention  282 
Differences in fastest sprint performance by intention to use supplements were observed in the 283 
positive-belief treatment (F (2,239) = 4.952, P = 0.008) but not in negative-belief treatment 284 
(F (2,197) = 1.247, P = 0.290) or control treatment (F (2,131) = 0.637, P = 0.530). In the positive-285 
belief treatment, fastest sprint performance in experimental compared to baseline for 286 
participants not intending to use supplements worsened by -1.10% ± 0.30%, performance of 287 
those undecided about supplement use worsened by -0.64% ± 0.43%, while performance of 288 
those intending to use supplements improved by 0.19% ± 0.24% (figure 3). In the positive-289 
belief treatment, change in performance from baseline and experimental also differed 290 
significantly between those participants intending to use supplements and those not intending 291 
to use supplements (1.29% ± 0.38%, P = 0.003, d = 0.49). No other within-treatment 292 
differences in fastest sprint performance between baseline and experimental were observed 293 
when classified by intention to use supplements (P >0.05; figure 3).  294 
Discussion 295 
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We aimed to replicate a previous study of placebo and nocebo effects in repeat sprint 296 
performance (5), albeit with the inclusion of a no-treatment control and a larger sample. We 297 
observed a mean nocebo effect in repeat sprint performance across the sample, but no mean 298 
placebo effect when compared to a no-treatment control. This suggests that, while receiving a 299 
purported harmful supplement significantly impaired performance, receiving a purported 300 
beneficial supplement did not enhance it. This finding differs to those of Beedie et al. (5) who 301 
reported significant placebo and nocebo effects in repeated sprinting.  302 
Although no mean placebo effect was observed, data from the positive-belief treatment did 303 
suggest that the performance of participants intending to use supplements improved to a greater 304 
degree in the experimental conditions than the performance of participants not intending to use 305 
supplements (d = 0.49, figure 3). These improvements were also greater than those observed 306 
among participants of equivalent intention in the negative-belief treatment (d = 0.51) and 307 
control treatment (d = 0.33). Given that effect sizes >0.2 are considered potentially beneficial 308 
for sport performance (23), these improvements in repeat sprint performance are likely 309 
meaningful for athletes. Furthermore, given that this relationship was observed only in the 310 
positive-belief treatment is of particular importance, as it supports our hypothesis that intention 311 
to use sports supplements might relate to placebo responding.   312 
While intention to use supplements influenced the placebo response, this relationship was not 313 
shown for prior supplement use (rpb = 0.071, P = 0.078). We did however examine the effect 314 
on performance of intention to use supplements and its interaction with prior supplement use. 315 
Intention to use supplements was strongly associated with prior supplement use (rpb = 0.666; 316 
P <0.001). This suggests that intention to use supplements is associated with prior supplement 317 
use and may moderate an athlete’s responsiveness to a placebo intervention. Although the 318 
design of this research precluded a robust test of this relationship, it is an intriguing research 319 
question that should be addressed in future research.  320 
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In consideration of the above, placebo responding is arguably a learned phenomenon. Research 321 
has shown that placebo effects can be initiated via verbal instructions (creating an expectation 322 
of a drug; (28)) and/or via repeat exposure to a drug with a subsequent placebo intervention 323 
mirroring the action of that drug (9). Previous experiences of a drug are therefore remembered, 324 
creating a memory of effective and ineffective treatments (29). This learning process is 325 
manifest in specific brain regions, with expectations and conditioning cues mediating and 326 
maintaining the turnover of, for example dopamine (19), and creating rewarding stimuli. On 327 
this basis, for a placebo responsive athlete, a placebo induced improvement in performance is 328 
the result of verbal information about the treatment (e.g. the suggestion that a supplement can 329 
improve performance) and/or cued or contextual conditioning (e.g. repeated exposure to a real 330 
treatment that results in treatment-like effects even when the treatment is replaced by a 331 
placebo). The athlete then recalls previous experiences and information about the effectiveness 332 
or ineffectiveness of the treatment, which shapes their subsequent intention to use it. This is 333 
perhaps a reason why athletes intending to use supplements are more likely to use these 334 
substances (17) and are arguably more likely to use other forms of performance enhancements 335 
(26).  336 
The finding that intention may influence the placebo effect has particular relevance to sports 337 
practitioners aiming to improve an athlete’s performance. Specifically, if improvements in 338 
performance following administration of a treatment (e.g. caffeine, sodium bicarbonate, β-339 
alanine) are the result of both pharmacological and placebo effects (3), but the athlete does not 340 
have a prior intention to use that treatment, it may not elicit a placebo response and the athlete 341 
may not fully benefit from the treatment. Ultimately, a treatment may be more effective when 342 
an athlete intends to use it than when they do not. Sport practitioners should therefore be aware 343 
of an athlete’s intentions towards a treatment prior to its administration, to ensure the 344 
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effectiveness of the treatment. This is also important in research, in which intentions towards 345 
a treatment could likewise influence outcomes.   346 
Any reference to the results of our study should take into account potential limitations.  First, 347 
we did not control for the presence of others or social support (e.g. cheering from teammates) 348 
during the sprint trials, and this may have affected performance. Second, while participants 349 
were asked to report on a Likert-type scale from 1 to 10 the degree to which they believed the 350 
treatment influenced their performance, they were not specifically asked if they believed the 351 
information they were given. We are therefore unable to assess the credibility of the belief-352 
manipulation. Finally, the use of self-reported sport supplement use may not be reliable, as 353 
there may be differences between what athletes’ report and what they actually think and/or do.  354 
Given that previous studies have used expensive and complex techniques such as positron 355 
emission tomography (2) and genotyping (18) to identify placebo responders/non-responders, 356 
a self-report measure could provide a cost-effective and practical alternative. Future research 357 
should aim to further explore the impact of intention on the effects of legitimate sports 358 
supplements, and how this could influence an athlete’s decision to use other forms of 359 
performance enhancements (e.g. doping). This understanding could enhance treatments, and 360 
inform athlete education and anti-doping strategy (26). 361 
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Tables  460 
Table 1. Demographics of participants between treatments   
    Positive Negative Control Overall 
n = 288 232 192 712 
      
Gender (%) Male 83.1 76.9 71.0 78.0 Female 16.9 23.1 29.0 22.0 
  
    
Age (%) 
18 to 24 66.7 65.0 79.0 69.4 
25 to 34 29.6 30.0 18.8 26.8 
35 to 44 3.7 5.1 2.3 3.8 
  
    
Sport (%) 
Rugby Union 46.2 42.7 22.3 39.0 
Soccer 42.9 36.9 44.1 41.3 
Field Hockey 5.3 8.9 2.8 5.8 
Other 5.6 11.6 30.7 13.9 
  
    
Ability (%) 
Club 25.5 35.4 21.1 27.5 
County 39.9 38.8 30.4 37.0 
Regional 25.9 19.6 32.7 25.7 
National 8.7 6.2 15.8 9.8 
 
 
    
Intention to use sport 
supplements (%) 
Not intending 23.9 33.5 35.6 30.0 
Undecided 21.6 18.9 18.1 19.8 
 Intending 54.5 47.6 46.3 50.2 
  
    
Use of Supplements (%) Yes 51.1 50.9 52.7 51.5 No 48.9 49.1 47.4 48.5 
 
 
    
Frequency of 
supplement use (%) 
Daily 24.1 26.6 26.2 25.5 
Weekly 22.6 21.0 24.4 22.5 
Monthly 4.4 3.3 1.8 3.4 
Never 48.9 49.1 47.6 48.6 
 
     
Mean ± SEM 
Years training 10.77 ± 0.38 10.94 ± 0.59 9.68 ± 0.45 10.68 ± 0.24  
Hours per week 
training 6.13 ± 0.25 5.93 ± 0.25 5.84 ± 0.30  5.9 ± 0.15 
Amount of supplements 
used 1.14 ± 0.10 1.11 ± 0.10 1.20 ± 0.13 1.09 ± 0.06 
SEM, standard error of the mean 
22 
 
Figure captions 461 
Figure 1. Average performance in each condition between treatments. Note: *baseline vs. 462 
experimental for negative-belief = P <0.05; **positive-belief and control vs. negative-belief = 463 
P <0.05. 464 
 465 
Figure 2. Average performance in condition by each treatment separated by participants’ 466 
intention to use sport supplements in the next three months. A. Positive-belief treatment. Note: 467 
*Baseline vs. Experimental for those not intending to use supplements = P <0.05; **intending 468 
to use supplements vs. not intending to use supplements = P <0.05. B. Negative-belief 469 
treatment. Note: *baseline vs. experimental for those not intending, undecided and intending 470 
to use supplements = P <0.05. C. No-treatment control. 471 
 472 
Figure 3. Differences in fastest performance between conditions, grouped by intention to use 473 
sport supplements. Note: *control vs. positive-belief and negative-belief = P <0.05, **positive-474 
belief vs. negative-belief = P <0.05, †positive-belief intention vs. positive-belief no intention 475 
= P <0.05 476 
  477 
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Figure 1  478 
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Figure 2  479 
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Figure 3. 480 
